Compounded tirzepatide
Sold by BloomMD · every compounded tirzepatide record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
What you actually pay
Per month
$324
| Medication · Monthly, lowest dose (2.2mg) | $249 |
|---|---|
| Required membership | $75 |
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Monthly, lowest dose (2.2mg) “Monthly 2.2–13 mg weekly $249–$459” source, read September 2, 2026 | Per month$249 | Charged today$249 |
| 3-month, lowest dose (2.2mg) “3-month 2.2–13 mg weekly $695–$1,225” source, read September 2, 2026 | Per month$232 | Charged today$695 |
| New patient starter, 12 weeks “New patient starter 12 weeks · 2.2 → 4.4 → 7 mg $749” source, read September 2, 2026 | Per month$250 | Charged today$749 |
We earn nothing from this link. BloomMD has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
- September 2, 2026 — $249
- September 3, 2026 — $249
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Pharmacy | Strive Compounding Pharmacy |
|---|---|
| Cancellation | “Subscription services : For subscription-based services, cancellations must be made at least 7 days before the next billing cycle to avoid charges. Once billed, subscriptions are non-refundable for that cycle but can be canceled for future billing periods.” |
| Membership | Required. $75 per month. “Membership starts at $75/month (does not include medication).” |
| Consult fee | None. “Yes, we offer a complimentary consultation.” |
Not yet checked: states and prescriber.
Recorded from bloommd.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.